Key Takeaways Gardasil sales dropped 40% in the first nine months of 2025 due to weak demand in China and Japan.Economic weakness in China and soft demand in Japan weigh on Gardasil's sales outlook.MRK's other vaccines, including ProQuad, Rotateq and Pneumovax 23, also saw sales decline.Merck (MRK) continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the prevention of certain cancers caused by human papillomavirus. Though the vaccine’s sales rose consistent ...

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)NurPhoto via Getty ImagesMerck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings exceeding expectations, the FDA's approval of Keytruda's new formulation, and an excellent upgrade ...

Key Points Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare. Lilly is close to releasing a pill form of its best-selling drug. 10 stocks we like better than Eli Lilly › Just a handful of companies have entered the rarefied trillionaire club. So far, it's been limited to huge technology companies like the Magnificent Seven, plus oil giant Saudi Aramco and Warren Buffett's conglomerate Berkshire Hathaway. But last ...

Key Takeaways MRK gains FDA approval for IV and SC Keytruda with Padcev for cisplatin-ineligible MIBC.KEYNOTE-905 showed a 60% cut in EFS risk and 50% OS improvement versus surgery alone.Approval follows study data supporting perioperative use of Keytruda plus Padcev regimen in MIBC.Merck (MRK) announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in combination with Pfizer’s ...

Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90. The firm cited business development and pipeline progress, no longer seeing a "major cliff" from the loss of Keytruda (a cancer medication) exclusivity. Today's pop has MRK trading at its highest levels since January, breaking into positive territory for 2025. The stock has added roughly 18% in November, and now sits ...

每经AI快讯，11月24日，默克公司盘前涨2.2%。 ...

20 November 2025 | 1:03AM EST Equity Research China Healthcare: Pharmaceuticals: Takeaways From Our China Biopharma Trip We hosted an investor trip to China (Nov 10-14) to meet local companies including 3SBio, Akeso (not covered), AbelZeta (private), BeOne, Duality (not covered), Eccogene (private), Everest Medicines, GenFleet (not covered), Grand Pharma (not covered), Hansoh, Hengrui, Henlius, InnoCare, Innovent, Kelun Biotech, Keymed (covered by Honglin Yan), Lepu Biopharma (not covered), Pyrotech (privat ...

Core Viewpoint - Merck has recommended that its shareholders reject Tutanota's "Mini-Tender" offer, indicating concerns over the offer's terms and potential implications for shareholders [1] Group 1: Company Actions - Merck's board of directors has expressed strong disapproval of Tutanota's offer, emphasizing that it is not in the best interest of shareholders [1] - The company has provided guidance to shareholders on the potential risks associated with accepting the Mini-Tender offer [1] Group 2: Shareholder Impact - The rejection of the Mini-Tender offer is aimed at protecting shareholders from potentially unfavorable terms that may not reflect the true value of their shares [1] - Merck encourages shareholders to remain informed and consider the implications of such offers on their investments [1]

RAHWAY, N.J .--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEXâ,ç¢ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-eifv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who ar. ...

By Mrinalika Roy (Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more than 35% rally in the company's ​stock this year has largely been driven by the explosive growth of the weight-loss drug market. In the last two years as new, highly effective ‌obesity treatments hit the market, the category has emerged as one of the most lucrative segments in heal ...